The investigators found that
pembrolizumab significantly improved the primary endpoint of progression - free survival by approximately four months compared to chemotherapy (10.3 months versus 6.0 months, hazard ratio [HR] 0.50).
Clinical trials of a new immunotherapy,
pembrolizumab, have shown that it prolongs life
significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma.